Sleep apnea affects millions globally, often lurking undetected until it begins impacting overall health. While high blood ...

“This is the first pharmacologic therapy that can treat obstructive sleep apnea ... or obese and have a specific type of ...

Try a single issue or save on a subscription Issues delivered straight to your door or device ...

Researchers, including experts from the University of Missouri School of Medicine, explored the use of senolytics—drugs ...

The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with ...

The Food and Drug Administration announced late Friday that it has approved Zepbound to treat obstructive sleep apnea for those ... a reduced-calorie diet and physical activity, the FDA said.

The FDA said the popular weight-loss drug should be combined with a reduced-calorie diet and increased physical activity. Obstructive sleep apnea happens ... But standard therapy with breathing ...

Sleep apnea, a condition that disrupts breathing during sleep, affects millions of people worldwide, especially adults over ...

Averaging up to 20% of weight loss, adults taking Tirzepatide had at least 25 fewer breathing interruptions each hour as they ...

The FDA advised that the medication be used in conjunction with a reduced-calorie diet and increased physical activity, both of which aid weight loss and, in turn, improve sleep apnea symptoms.

“This is the first pharmacologic therapy that can treat obstructive ... type of sleep apnea known as obstructive sleep apnea, which is a physical condition in which the muscles of the throat ...

for treating moderate to severe obstructive sleep apnea (OSA) in adults with obesity. The new indication is for use in combination with reduced-calorie diet and increased physical activity.